Aβ binding molecules
    3.
    发明授权
    Aβ binding molecules 有权
    Abeta结合分子

    公开(公告)号:US07575747B2

    公开(公告)日:2009-08-18

    申请号:US10544050

    申请日:2004-02-06

    IPC分类号: A61K39/395 C07K16/18

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括使用衍生自鼠抗体266的互补决定区的鼠抗体266的人源化变体的分离的抗体或其片段。变体抗体可用于治疗或预防与Aβ相关的病症和疾病,包括阿尔茨海默氏病 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。

    Aβ binding molecules
    4.
    发明授权
    Aβ binding molecules 有权
    A&bgr 结合分子

    公开(公告)号:US08105597B2

    公开(公告)日:2012-01-31

    申请号:US12504818

    申请日:2009-07-17

    IPC分类号: A61K39/395 C07K16/18

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括分离的抗体或其片段,其是使用来自鼠抗体266的互补决定区的鼠抗体266的人源化变体。变体抗体可用于治疗或预防与A&bgr相关的病症和疾病,包括阿尔茨海默病 疾病。 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。

    Aβ binding molecules
    5.
    发明授权
    Aβ binding molecules 有权
    Abeta结合分子

    公开(公告)号:US08623365B2

    公开(公告)日:2014-01-07

    申请号:US13332753

    申请日:2011-12-21

    IPC分类号: A61K39/395

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括使用衍生自鼠抗体266的互补决定区的鼠抗体266的人源化变体的分离的抗体或其片段。变体抗体可用于治疗或预防与Aβ相关的病症和疾病,包括阿尔茨海默氏病 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。

    ABETA BINDING MOLECULES
    7.
    发明申请
    ABETA BINDING MOLECULES 有权
    ABETA结合分子

    公开(公告)号:US20090297505A1

    公开(公告)日:2009-12-03

    申请号:US12504818

    申请日:2009-07-17

    摘要: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

    摘要翻译: 本发明包括分离的抗体或其片段,其是使用来自鼠抗体266的互补决定区的鼠抗体266的人源化变体。变体抗体可用于治疗或预防与Aβ相关的病症和疾病,包括阿尔茨海默氏病 。 唐氏综合征,脑淀粉样血管病,轻度认知障碍等。